Definium Therapeutics, Inc. is trading 4.1% down at $23.58 today as a stronger-than-expected U.S. jobs report and rising interest rate expectations weigh on growth-oriented stocks.
- The decline follows a multi-day run-up, with the stock giving back a portion of its recent gains amid a broader market risk-off sentiment.
- No company-specific news or analyst rating changes were reported on June 5, indicating the price action is tied to macroeconomic factors affecting the growth sector.